NCT01283230

Brief Summary

This is a prospective cohort Study for evaluation of liver fibrosis staging with acoustic radiation force impulse elastography in patients with chronic liver disease and healthy liver/kidney donors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

January 21, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 25, 2011

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
Last Updated

February 2, 2012

Status Verified

February 1, 2012

Enrollment Period

9 months

First QC Date

January 21, 2011

Last Update Submit

February 1, 2012

Conditions

Keywords

ARFI imagingnormal valueschronic liver diseaseliver donorskidney donors

Outcome Measures

Primary Outcomes (1)

  • Evaluation of ARFI velocity in healthy donors and patients with chronic liver disease

    Measurement of ARFI velocity is non-invsive ultrasonographic technique. It is performed with a abdominal convex probe which is same probe as conventional ultrasonography. Short-duration acoustic radiation forces result in shear-wave propagation away from the region of excitation and are tracked using ultrasonic correlation-based methods. This results are called ARFI velocity which is expressed as meters per second

    2 years

Study Arms (2)

chronic liver disease

Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.

Device: Acoustic radiation force impulse imaging

Healthy liver and kidney donor

Healthy liver and kidney donor who have normal liver condition

Device: Acoustic radiation force impulse imaging

Interventions

Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.

Also known as: ARFI imaging
Healthy liver and kidney donorchronic liver disease

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with chronic liver disease, Healthy liver and kidney donors

You may qualify if:

  • Age \> 20 years
  • chronic liver disease (hepatitis B, hepatitis C, liver cirrhosis) patients who are planned to liver biopsy
  • Healthy liver and kidney donors
  • The patients who is willing and able to provide written informed consent to participate in this study

You may not qualify if:

  • Decompensated liver cirrhosis
  • Patients with liver congestion due to heart dysfunction
  • Patients who previously take antiviral agent and antifibrotic agent
  • Healthy liver and kidney donors with any laboratory abnormalities regarding liver condition (Platelet count \< 150 x 103/ul, Fasting glucose \> 110 mg/dl, AST \> 40 IU/L, ALT\> 40 IU/L, Albumin \< 3.3 g/dl, Total bilirubin \> 1.2 mg/dl, GGT\> 54 IU/L, ALP \> 115 IU/L , Ferritin \> 322 ng/ml)
  • A history of any other medical disease or condition that would make the patients unsuitable for this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, 120-752, South Korea

Location

MeSH Terms

Interventions

Elasticity Imaging Techniques

Intervention Hierarchy (Ancestors)

UltrasonographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Kwang-Hyub Han, MD

    Department of Internal Medicine, Yonsei University College of Medicine

    STUDY CHAIR
  • Seung Up Kim, MD

    Department of Internal Medicine, Yonsei University College of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 21, 2011

First Posted

January 25, 2011

Study Start

July 1, 2010

Primary Completion

April 1, 2011

Study Completion

April 1, 2011

Last Updated

February 2, 2012

Record last verified: 2012-02

Locations